Other groups used their CRC organoid biobanks to perform high-throughput analyses to identify potential inhibitors of KRAS and EGFR oncogenes [110,111] and to study the regenerative response of normal intestinal organoids to nearly three thousand compounds [112]. This evidence concerns the gene KRAS and colorectal carcinoma.